Novus Therapeutics, Inc. News Releases http://ir.novustherapeutics.com/ Novus Therapeutics, Inc. News Releases en Novus Therapeutics Reports First Quarter 2019 Financial Results http://ir.novustherapeutics.com/news-releases/news-release-details/novus-therapeutics-reports-first-quarter-2019-financial-results IRVINE, Calif. --(BUSINESS WIRE)--May 14, 2019-- Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced financial results for the quarter ended March 31, 2019 . Tue, 14 May 2019 16:05:00 -0400 Novus Therapeutics, Inc. News Releases 7856 Novus Therapeutics Announces Closing of $10.7 Million Registered Direct Offering Priced At-the-Market http://ir.novustherapeutics.com/news-releases/news-release-details/novus-therapeutics-announces-closing-107-million-registered IRVINE, Calif. --(BUSINESS WIRE)--May 2, 2019-- Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced the closing of its previously announced registered direct Thu, 02 May 2019 16:01:00 -0400 Novus Therapeutics, Inc. News Releases 7811 Novus Therapeutics Announces $10.7 Million Registered Direct Offering Priced At-the-Market http://ir.novustherapeutics.com/news-releases/news-release-details/novus-therapeutics-announces-107-million-registered-direct IRVINE, Calif. --(BUSINESS WIRE)--Apr. 30, 2019-- Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that it has entered into definitive agreements with several Tue, 30 Apr 2019 09:13:00 -0400 Novus Therapeutics, Inc. News Releases 7796 Novus Therapeutics Announces Results of Two Single-Dose OP0201 Phase 1 Clinical Trials http://ir.novustherapeutics.com/news-releases/news-release-details/novus-therapeutics-announces-results-two-single-dose-op0201 OP0201 Was Safe and Well-Tolerated in Healthy Adults and Adults with Acute Otitis Media IRVINE, Calif. --(BUSINESS WIRE)--Apr. 22, 2019-- Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and Mon, 22 Apr 2019 08:00:00 -0400 Novus Therapeutics, Inc. News Releases 7781 Novus Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Clinical Updates http://ir.novustherapeutics.com/news-releases/news-release-details/novus-therapeutics-reports-fourth-quarter-and-full-year-2018 IRVINE, Calif. --(BUSINESS WIRE)--Mar. 28, 2019-- Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced financial results for the quarter and year ended December 31, Thu, 28 Mar 2019 08:00:00 -0400 Novus Therapeutics, Inc. News Releases 7771 Novus Therapeutics to Participate in the 8th Annual SVB Leerink Global Healthcare Conference http://ir.novustherapeutics.com/news-releases/news-release-details/novus-therapeutics-participate-8th-annual-svb-leerink-global IRVINE, Calif. --(BUSINESS WIRE)--Feb. 20, 2019-- Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that the company will participate at the 8th Annual SVB Wed, 20 Feb 2019 08:00:00 -0500 Novus Therapeutics, Inc. News Releases 7741 Novus Therapeutics Doses First Patients in Phase 2a Trial of OP0201 http://ir.novustherapeutics.com/news-releases/news-release-details/novus-therapeutics-doses-first-patients-phase-2a-trial-op0201 IRVINE, Calif. --(BUSINESS WIRE)--Feb. 19, 2019-- Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that it has dosed the first patients in a phase 2a trial of Tue, 19 Feb 2019 08:00:00 -0500 Novus Therapeutics, Inc. News Releases 7736 Company Profile for Novus Therapeutics, Inc. http://ir.novustherapeutics.com/news-releases/news-release-details/company-profile-novus-therapeutics-inc Novus Therapeutics, Inc. (“Novus”) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (“ENT”). Novus has two technologies, each that has the potential to be developed for multiple ENT indications. Fri, 15 Feb 2019 23:14:00 -0500 Novus Therapeutics, Inc. News Releases 7731 Novus Therapeutics Doses First Subjects in Phase 1 Pharmacodynamics Study of OP0201 http://ir.novustherapeutics.com/news-releases/news-release-details/novus-therapeutics-doses-first-subjects-phase-1-pharmacodynamics IRVINE, Calif. --(BUSINESS WIRE)--Feb. 11, 2019-- Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that it has dosed the first adult subjects in study C-001, a Mon, 11 Feb 2019 08:00:00 -0500 Novus Therapeutics, Inc. News Releases 7716 Novus Therapeutics Advances OP0201 Development Program Across Several Clinical Trials http://ir.novustherapeutics.com/news-releases/news-release-details/novus-therapeutics-advances-op0201-development-program-across Screening Initiated for Phase 1 Pharmacodynamic Effects Trial (Study C-001) Screening Initiated for Second Cohort of Phase 1 Trial in Healthy Adults (Study C-002) Enrollment Completed in Phase 1 Trial in Adults with Acute Otitis Media (Study C-004) New Phase 2a Trial in Infants and Children with Wed, 30 Jan 2019 08:00:00 -0500 Novus Therapeutics, Inc. News Releases 7711